Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund.
Luigi CerboneSara DelfantiStefania CrivellariAntonina Maria De AngelisLaura MazzeoClaudia ProtoMario Alberto OcchipintiGiuseppe Lo RussoChiara DellepianeFederica BielloIrene AlabisoFrancesco VerderameRoberta GaunaIrene De SimoneFederica CupponeSandra PetragliaGiulia PaselloGiovanni Luca CeresoliMarina Chiara GarassinoValter TorriFederica GrossoPublished in: Tumori (2024)
Nivolumab as a single agent is fairly active in a cohort of unselected pretreated pleural mesothelioma patients. Further investigations on clinical and translational factors are needed to define which patient might benefit most from nivolumab treatment in pleural mesothelioma.